Roche asks:
Between 2 June 2025 and 1 October 2025, which of the following major medical diagnostics companies will first announce regulatory approval from any national (e.g., US FDA) or supranational (e.g., EU's EMA) public regulatory body for a novel, AI-driven diagnostic tool intended for clinical decision-making in oncology for human patients?
Closing Sep 30, 2025 07:01AM UTC
AI has the potential to revolutionize the diagnosis of cancer (Cancer Research Institute, National Institutes of Health). An announced approval of a tool produced in collaboration with another organization will count. The announcement must explicitly characterize the tool as being an AI or machine learning tool. Oncology is the branch of medicine specializing in the diagnosis and treatment of cancer (Cancer.gov - Oncology). Any type of approval that allows the company's tool to be utilized on actual patients outside of a clinical trial will count, including fast-track and emergency authorizations. In the event that two or more companies simultaneously (i.e., exact same date and time) announce a qualifying approval, the answer option listed first (top to bottom) will be considered to have announced first. An already-approved tool of a firm acquired by a major medical diagnostics company will not count.
Confused? Check our FAQ or ask us for help. To learn more about Good Judgment and Superforecasting, click here.
To learn more about how you can become a Superforecaster, see here. For other posts from our Insights blog, click here.
| Possible Answer | Crowd Forecast | Change in last 24 hours | Change in last week | Change in last month |
|---|---|---|---|---|
| GE Healthcare | 6.25% | +1.25% | +0.51% | +1.25% |
| Philips Healthcare | 4.63% | +0.63% | -0.15% | -3.37% |
| Roche | 11.75% | -0.25% | -0.90% | +2.75% |
| Siemens Healthineers | 7.75% | -0.25% | +2.14% | +0.75% |
| None of the above | 69.63% | -1.37% | -1.59% | -1.37% |